Zynerba’s Cannabidiol Failure in Focal Seizures Not So Clear-Cut
Zynerba’s gel formulation of cannabidiol has disappointed in top-line data from a Phase II study in epilepsy patients with focal seizures, but some signals of efficacy in a companion study, and expected data from studies in two other indications, might influence future development plans.
You may also be interested in...
Positive Phase II study of cannabinoid ZYN002 sends stock soaring, but the trial was very small with an open-label design, and response was mostly recorded by caregivers.
Ten clinical trial data readouts to watch for in the third quarter of 2017 that are expected to shift stocks and potentially change standard of care options in some disease areas.
Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.